majority of cases. 1 The prevalence of AF is increasing in both developed and developing countries, owing to an aging population, and this increase is predicted to continue over the coming decades. 2 Patients with AF have a 5-fold greater risk of stroke and frequently present in elderly patients. Common risk factors for stroke are hypertension, diabetes, heart failure, smoking, and prior stroke or transient ischemic attack (TIA). 3, 4 In addition to an increased risk of stroke, AF patients frequently present with comorbid myocardial infarction, dementia, and chronic kidney disease. 5, 6 The Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF) is an ongoing prospective, international, multicentre registry of adult patients with newly diagnosed NVAF and one or more additional risk factors for stroke. 7 Since December 2009, more than 50 000
patients have been enrolled in the registry from 35 countries and patient follow-up is anticipated to end in the third quarter of 2018.
Major goals of the registry are to identify best practices as well as deficiencies in stroke prevention strategies for AF patients and to describe how patient care has evolved over time. As in all registries, there might be substantial regional and intraregional differences among baseline characteristics and use of antithrombotic therapies in patients with new NVAF. 8 In 2010, the Global Burden of Disease Study estimated that ageadjusted prevalence of AF in Latin America was 737.9 per 100 000 men and 440.3 per 100 000 women, which is higher than the global average estimated to be 596 per 100 000 men and 373 per 100 000 women. 9 It is likely that the true prevalence of AF, in general, may be even higher due to asymptomatic or unrecognized AF, which is estimated to account for up to 27% undiagnosed AF patients. 10 In this paper, we analyzed the baseline characteristics, patterns of antithrombotic therapies and 1-year outcomes in four Latin American countries, Argentina, Brazil, Chile, and Mexico that participated in the GARFIELD-AF.
| METHODS

| Study design and participants
GARFIELD-AF is a non-interventional, observational, worldwide study of NVAF, as described in detail previously. 7 Patients (≥18 years) were diagnosed with AF according to standard local procedures within the previous 6 weeks and had at least 1 additional factor(s) for stroke as judged by the study investigator. Risk factors were not pre-specified in the protocol nor were they limited to the components of existing risk stratification schemes. The study excluded patients with a transient, reversible cause of NVAF, and patients for whom follow-up to 2 years was not envisaged or possible. 7 Consecutive patients were enrolled prospectively into five sequential cohorts (plus one retrospective cohort of 5000 patients). Investigator sites were randomly selected 11 and were representative of the care settings in each country.
| Data collected at baseline
Baseline data from the patients were collected at the time of diagnosis and included the type of AF, patient demographics, medical history, 3 | RESULTS
| Patient population
A total of 4162 patients with NVAF aged ≥18 years were enrolled in 
| Risk factors
Baseline characteristics of patients are shown in Table 1 with patients from Brazil (11.5%), Chile (9.8%), and Argentina (7.4%).
The prevalence of moderate-to-severe CKD ranged from 4.5% in Argentina to 9.0% in Brazil (Table 1) . Despite these differences, the mean (SD) CHA 2 DS 2 -VASc score was similar in patients from Argentina, Brazil, Chile, and Mexico: 3.5 (1.6), 3.3 (1.5), 3.2 (1.7), and 3.1 (1.5), respectively.
| Antithrombotic treatment for stroke prevention
Upon diagnosis of AF, 39.9% of patients from all four countries were prescribed VKAs ± AP therapy, 21.8% NOACs ± AP therapy and 24.1% AP alone. 14.1% of patients received no antithrombotic treatment (Table 2 ).
Notable differences in patterns of antithrombotic treatment were found between the countries. The use of NOAC ± AP was higher in 
| Reasons for anticoagulant therapy was not used
The main reason for not giving an AC to patients at moderate-to-high risk of stroke varied between countries but was most frequently the physician's choice (53.8%) (Table S1 , Supporting Information).
| INR and TTR values
The distribution of INR and TTR values for patients receiving VKA ± AP at baseline is presented in 
| DISCUSSION
In this paper, we describe the baseline characteristics, antithrombotic treatment patterns, quality of VKA control and event rates for major clinical outcomes in AF patients from four countries in Latin America, who were enrolled in the GARFIELD-AF registry.
Even though patients were from the same region, the baseline characteristics and comorbidities were remarkably different for patients from each country. Patients from Chile, for example, were typically older than other in this countries analysis, with a higher incidence of obesity, although these patients had a lower incidence of vascular disease. Interestingly, a history of stroke and TIA was more than twice as frequent in Mexico (16.5%) compared with patients from Argentina (7.4%).
At the time of AF diagnosis, there were also major differences in the choice of AC treatment for stroke prophylaxis in Argentina, Brazil, Chile, and Mexico. The prescription of antithrombotic therapy was highest in Chile where most patients received VKA ± AP (70.0%) rather than NOACs ± AP (12.3%). This was in contrast to Mexico, where prescription of NOACs ± AP was more common (28.8%), with a smaller number of patients receiving VKA ± AP (24.3%). These differences might be related to the differences in patients recruited in countries, differences in enrolling sites and public or private health policies at each country.
Although key guidelines in Latin America, including the Brazilian It has been demonstrated that the benefit of AC therapy significantly outweighs the risk of bleeding for AF patients with a CHADS 2 or CHA 2 DS 2 -VASc score of ≥2. [21] [22] [23] In GARFIELD-AF, over four-fifths of patients from Latin America were classified as having a moderateto-high risk of stroke (ie, CHA 2 DS 2 -VASc score ≥ 2). Of these patients, 35.9% did not receive an anticoagulant. It is widely accepted that AC reduces stroke risk in AF patients; VKAs reduce the risk of stroke by 66% and the risk of death by 28% compared to no therapy. 33 The new Brazilian Guideline from 2016 34 and Mexican Guidelines, 23 for example, indicates the use of NOACs in a similar manner to the European guidelines. This has also been stressed by different groups of Latin American investigators. 35, 36 All-cause mortality was the most frequent major clinical outcome, nearly 4-fold higher than the rate of stroke/SE, and 6-fold higher than the rate of major bleeding. Mortality rates from the combined experience: Argentina, Brazil, Chile, and Mexico are higher to those reported in the entire GARFIELD-AF registry. 37 However, these numbers are consistent with other reports from Latin America, derived from clinical trials, such as ENGAGE-AF and ROCKET-AF. 27, 38 In addition to the poor management of antithrombotic therapies, it is possible that the reasons for the high mortality rates of Latin American patients with AF are related to a higher rate of comorbidities or sociocultural problems, such as difficulties in access to healthcare, lower educational levels, etc. Considering the AC treatment underuse, poor VKA control, and high mortality rate which are challenge for our health systems, developing countries should be warned and achieve their evidence. If our results are reproduced, strategies should be established to improve AF patient care. Whatever the reasons, there is room for improvement in the management of AF patients in Argentina, Brazil, Chile, and Mexico.
| LIMITATIONS
This registry is limited to patients with newly diagnosed AF and the study was mainly conducted by the cardiologists. As with all registries, there may be a bias in the selection of patients and medical centers and so the results may not reflect the experience in all centers in these countries.
| CONCLUSIONS
This paper describes the baseline characteristics and patterns of antithrombotic treatment in patients from four Latin American countries, Argentina, Brazil, Chile, and Mexico. Over one-third of patients with a moderate-to-high risk of stroke received no AC therapy, highlighting the need for better adherence to evidence-based guidelines on stroke prevention in AF.
